Structural Analysis of Some Pyrrolopyrimidine Derivatives and Examining their Binding Affinity against Cyclooxygenase-2 Enzyme

Year 2021, , 14 - 23, 15.12.2021

Kun Harismah , Mahmoud Mırzaeı , Kimia Ghafarı

https://doi.org/10.33435/tcandtc.1001021

Cited By: 3

Abstract

This work was performed to investigate structural features of ten models (L1-1L10) of pyrrolopyrimidine derivatives in addition to evaluating their activity against the cyclooxygenase-2 (COX-2) enzyme target. In this regard, celecoxib (CEL) was employed as a reference model for evaluating features of the investigated models. Frontier molecular orbitals features were evaluated for the models including the highest occupied and the lowest unoccupied molecular orbitals (HOMO and LUMO) in addition to evaluating chemical hardness and softness (H and S) features. Afterwards, molecular docking (MD) simulations were performed for examining the contribution of each compound against the COX-2 enzyme for formation of ligand-target complexes. The models showed that the investigated structures could work as efficient ligands for building string complexes with the COX-2 target, in which some of them with CN, F, and OMe functional groups were also more efficient than the reference CEL drug. As a consequence, details of ligand-target complex formations including types of interactions and surrounding amino acids were all recognized for the models systems.

Keywords

Pyrrolopyrimidine, Celecoxib, COX-2, Anti-inflammatory, DFT, In silico

Supporting Institution

Isfahan University of Medical Sciences

Project Number

299092

Thanks

The support of this work by the research council of Isfahan University of Medical Sciences under grant number 299092 is acknowledged.

References

• S. Pathania, R.K. Rawal, Pyrrolopyrimidines: an update on recent advancements in their medicinal attributes. European Journal of Medicinal Chemistry, 157 (2018) 503-526.
• F. Ran, Y. Liu, X. Chen, H. Zhuo, C. Xu, Y. Li, X. Duan, G. Zhao, Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma. Bioorganic Chemistry, 112 (2021) 104968.
• Y. Liu, Z. Zhang, F. Ran, K. Guo, X. Chen, G. Zhao, Extensive investigation of benzylic N-containing substituents on the pyrrolopyrimidine skeleton as Akt inhibitors with potent anticancer activity. Bioorganic Chemistry, 97 (2020) 103671.
• Y.D. Gao, D. Feng, R.P. Sheridan, G. Scapin, S.B. Patel, J.K. Wu, X. Zhang, R. Sinha-Roy, N.A. Thornberry, A.E. Weber, T. Biftu, Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors. Bioorganic & Medicinal Chemistry Letters, 17 (2007) 3877-3879.
• O.M. Khalil, A.M. Kamal, S. Bua, H.E. Teba, Y.M. Nissan, C.T. Supuran, Pyrrolo and pyrrolopyrimidine sulfonamides act as cytotoxic agents in hypoxia via inhibition of transmembrane carbonic anhydrases. European Journal of Medicinal Chemistry. 188 (2020) 112021.
• S.S Fatahala, S. Mahgub, H. Taha, R.H. Abd-El Hameed, Synthesis and evaluation of novel spiro derivatives for pyrrolopyrimidines as anti-hyperglycemia promising compounds. Journal of Enzyme Inhibition and Medicinal Chemistry, 33 (2018) 809-817.
• Y. Saito, H. Yuki, M. Kuratani, Y. Hashizume, S. Takagi, T. Honma, A. Tanaka, M. Shirouzu, J. Mikuni, N. Handa, I. Ogahara, A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo. Science Translational Medicine, 5 (2013) 52.
• P. Arora, V. Arora, H.S. Lamba, D. Wadhwa, Importance of heterocyclic chemistry: a review. International Journal of Pharmaceutical Sciences and Research, 3 (2012) 2947.
• R. Rajakariar, M.M. Yaqoob, D.W. Gilroy, COX-2 in inflammation and resolution. Molecular Interventions. 6 (2006) 199.
• G.A. Green, Understanding NSAIDs: from aspirin to COX-2. Clinical Cornerstone,3 (2001) 50-59.
• S. Bindu, S. Mazumder, U. Bandyopadhyay, Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective. Biochemical Pharmacology, 180 (2020) 114147.
• S.L. Manju, K.R. Ethiraj, G. Elias, Safer anti-inflammatory therapy through dual COX-2/5-LOX inhibitors: a structure-based approach. European Journal of Pharmaceutical Sciences, 121 (2018) 356-381.
• M. Mirzaei, K. Harismah, M. Soleimani, S. Mousavi, Inhibitory effects of curcumin on aldose reductase and cyclooxygenase-2 enzymes. Journal of Biomolecular Structure and Dynamics, (2020) 1-7.
• K. Harismah, M. Mirzaei, Steviol and iso-steviol vs. cyclooxygenase enzymes: in silico approach. Lab-in-Silico, 1 (2020) 11-15.
• Z. Li, X. Li, M.B. Su, L.X. Gao, Y.B. Zhou, B. Yuan, X. Lyu, Z. Yan, C. Hu, H. Zhang, C. Luo, Discovery of a potent and selective NF-κB-inducing kinase (NIK) inhibitor that has anti-inflammatory effects in vitro and in vivo. Journal of Medicinal Chemistry, 63 (2020) 4388-4407.
• F. Islam, M.R. Rahman, M.M. Matin, The effects of protecting and acyl groups on the conformation of benzyl α-L-rhamnopyranosides: an in silico study. Turkish Computational and Theoretical Chemistry, 5 (2021) 39-50.
• M. Missioui, S. Mortada, W. Guerrab, G. Serdaroğlu, S. Kaya, J.T. Mague, E.M. Essassi, M.E. Faouzi, Y. Ramli, Novel antioxidant quinoxaline derivative: Synthesis, crystal structure, theoretical studies, antidiabetic activity and molecular docking study. Journal of Molecular Structure, 1239 (2021) 130484.
• Y. Ashjaee, H. Zandi, Molecular analysis of 5-COR derivatives of uracil and evaluating their affinity against the MPro target of COVID-19. Advanced Journal of Science and Engineering, 2 (2021) 79-85.
• A.A. Pari, M. Yousefi. Exploring formations of thio-thiol and keto-enol tautomers for structural analysis of 2-thiouracil. Advanced Journal of Science and Engineering, 2 (2021) 111-114.
• M. Ghanadian, Z. Ali, I.A. Khan, P. Balachandran, M. Nikahd, M. Aghaei, M. Mirzaei, S.E. Sajjadi, A new sesquiterpenoid from the shoots of Iranian Daphne mucronata Royle with selective inhibition of STAT3 and Smad3/4 cancer-related signaling pathways. DARU Journal of Pharmaceutical Sciences, 28 (2020) 253-262.
• Z. Farahbakhsh, M.R. Zamani, M. Rafienia, O. Gülseren, M. Mirzaei, In silico activity of AS1411 aptamer against nucleolin of cancer cells. Iranian Journal of Blood and Cancer, 12 (2020) 95-100.
• M.J. Frisch, et al., Gaussian 09, Revision D.01, Gaussian. Inc., Wallingford CT, 2013.
• J.L. Mateos, Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review. Drugs of Today, 46 (2010) 1-25.
• D.S. Goodsell, C. Zardecki, L. Di Costanzo, J.M. Duarte, B.P. Hudson, I. Persikova, J. Segura, C. Shao, M. Voigt, J.D. Westbrook, J.Y. Young. RCSB Protein Data Bank: enabling biomedical research and drug discovery. Protein Science. 29 (2020) 52-65.
• N.S. Patil, S.H. Rohane, Organization of SwissDock: in study of computational and molecular docking study. Asian Journal of Research in Chemistry, 14 (2021) 145-148.